Shareholder information

Here’s where you’ll find services and information for our shareholders, both UK and international.

 

Share price information >

See the latest share price, share price chart, and share price calculator.

ADR programme >

American Depositary Receipts for US shareholders.

Advisors and Investor contacts >

All the key contacts related to investing in Vernalis.

Analyst coverage >

What do the analysts who follow Vernalis say about the company?

Shareholder services >

Download change of address, stock transfer forms, etc.

Shareholder alert >

If you have received unsolicited contact regarding the purchase of your Vernalis shares please read this document. Download here

Latest News

FDA Issues a Complete Response Letter on CCP-08 NDA

Vernalis plc announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-08. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch